Cancer Discovery 2019-Aug
Merck LAPs Up Tilos for Its TGFβ-Targeting Tech.
只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
关键词
抽象
Merck will spend up to $773 million to acquire Tilos Therapeutics, a 3-year-old startup with a series of preclinical-stage antibodies that prevent the activation and release of TGFβ, a cytokine involved in thwarting the effectiveness of cancer immunotherapies.